Skip to content

NYSE · CIK 0001795091

OSTX OS Therapies Inc

Insider trading from SEC Form 4. Last filing Feb 13, 2026. Close $1.62 on Oct 9, 2026, +40% from the 52-week low and -28% from the high.

OS Therapies Inc (OSTX) has 24 SEC Form 4 filings on file from 9 insiders, the latest filed on Feb 13, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.

4 open-market trades have been scored at OSTX. The newest: Shalom Auerbach (10% owner) sold $164k of stock on May 7, 2025, filed May 9, 2025, scored 23 (weak). The largest of the 4 shown: Shalom Auerbach (10% owner) sold $284k on Feb 14, 2025, scored 26 (weak).

OSTX closed at $1.62 on Oct 9, 2026, 40% above its 52-week low and 28% below its 52-week high.

1 Form 144 notice of planned sales is on file, the latest filed May 7, 2025.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
9
with a Form 4 at this company

Price and insider trades, last year

OSTXOct 9, 2026 · close 1.62

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at OS Therapies Inc, scored.

ScoreInsiderValueHoldingsPrice contextFiled
23WeakShalom Auerbach
owner
sell
$164k
82,000 shares
-3%+64% from low-64% from high
21WeakShalom Auerbach
owner
sell
$82k
60,012 shares
-2%+2% from low-74% from high
26WeakShalom Auerbach
owner
sell
$284k
100,000 shares
-4%-
22WeakShalom Auerbach
owner
sell
$113k
16,720 shares
-1%-

Planned sales

Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales

FiledSellerSharesValueSale datePast 3 months
May 7, 2025 Einodmil LLC
10% stockholder
1,200,000
4.47% of outstanding
$2.8MMay 7, 2025$366k

Transactions

Every row filed, 47 in all.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Jan 22, 2026Karim Galzahr
director
AGrant or award
Stock options (right to buy)derivative
+50,000$0.00$050,000Feb 13, 2026
Jan 22, 2026Olivier Roger Jarry
director
AGrant or award
Stock options (right to buy)derivative
+50,000$0.00$050,000Feb 13, 2026
Jan 22, 2026Christopher P. Acevedo
Chief Financial Officer
AGrant or award
Stock options (right to buy)derivative
+100,000$0.00$0100,000Feb 13, 2026
Jan 22, 2026Avril Suzette McKean-Dieser
director
AGrant or award
Stock options (right to buy)derivative
+50,000$0.00$050,000Feb 13, 2026
Jan 22, 2026Paul A. Romness
President and CEO
AGrant or award
Stock options (right to buy)derivative
+1,000,000$0.00$01,000,000Feb 13, 2026
Jan 22, 2026Robert Petit
See Remarks
AGrant or award
Stock options (right to buy)derivative
+100,000$0.00$0100,000Feb 13, 2026
Oct 21, 2025Paul A. Romness
President and CEO
AGrant or award
Stock options (right to buy)derivative
+1,000,000$0.00$01,000,000Feb 13, 2026
Jan 22, 2026John Ciccio
director
AGrant or award
Stock options (right to buy)derivative
+50,000$0.00$050,000Feb 13, 2026
Jan 22, 2026Theodore F. Search
director
AGrant or award
Stock options (right to buy)derivative
+50,000$0.00$050,000Feb 13, 2026
Oct 21, 2025Karim Galzahr
director
AGrant or award
Stock options (right to buy)derivative
+140,000$0.00$0140,000Dec 19, 2025
Oct 21, 2025Olivier Roger Jarry
director
AGrant or award
Stock options (right to buy)derivative
+140,000$0.00$0140,000Dec 19, 2025
Oct 21, 2025Christopher P. Acevedo
Chief Financial Officer
AGrant or award
Stock options (right to buy)derivative
+200,000$0.00$0200,000Dec 19, 2025
Oct 21, 2025Avril Suzette McKean-Dieser
director
AGrant or award
Stock options (right to buy)derivative
+140,000$0.00$0140,000Dec 19, 2025
Oct 21, 2025Paul A. Romness
President and CEO
AGrant or award
Stock options (right to buy)derivative
+1,950,000$0.00$01,950,000Dec 19, 2025
Oct 21, 2025Robert Petit
See Remarks
AGrant or award
Stock options (right to buy)derivative
+500,000$0.00$0500,000Dec 19, 2025
Oct 21, 2025John Ciccio
director
AGrant or award
Stock options (right to buy)derivative
+140,000$0.00$0140,000Dec 19, 2025
Oct 21, 2025Theodore F. Search
director
AGrant or award
Stock options (right to buy)derivative
+140,000$0.00$0140,000Dec 19, 2025
May 7, 2025Shalom Auerbach
owner
SOpen-market sale
Common Stock, par value $0.001 per shareindirect: See Footnote
-82,000$2.00$164k2,664,199May 9, 2025
Apr 9, 2025Shalom Auerbach
owner
SOpen-market sale
Common Stock, par value $0.001 per shareindirect: See Footnote
-50,012$1.35$68k2,756,199Apr 11, 2025
Apr 10, 2025Shalom Auerbach
owner
SOpen-market sale
Common Stock, par value $0.001 per shareindirect: See Footnote
-10,000$1.39$14k2,746,199Apr 11, 2025
Feb 27, 2025Shalom Auerbach
owner
JOther
Common Stock, par value $0.001 per shareindirect: See Footnote
-225,000$1.64$369k2,806,211Feb 28, 2025
Feb 14, 2025Shalom Auerbach
owner
SOpen-market sale
Common Stock, par value $0.001 per shareindirect: See Footnote
-100,000$2.84$284k2,431,211Feb 18, 2025
Jan 15, 2025Shalom Auerbach
owner
SOpen-market sale
Common Stock, par value $0.001 per shareindirect: See Footnote
-16,720$6.74$113k2,531,211Jan 17, 2025
Aug 2, 2024Shalom Auerbach
owner
CConversion
Common Stock, par value $0.001 per share
+23,371--23,371Jan 14, 2025
Aug 2, 2024Shalom Auerbach
owner
CConversion
Common Stock, par value $0.001 per shareindirect: See Footnote
+633,980--1,438,355Jan 14, 2025
Aug 2, 2024Shalom Auerbach
owner
CConversion
Common Stock, par value $0.001 per shareindirect: See Footnote
+27,486--1,465,841Jan 14, 2025
Aug 2, 2024Shalom Auerbach
owner
CConversion
Common Stock, par value $0.001 per shareindirect: See Footnote
+270,465--1,736,306Jan 14, 2025
Aug 2, 2024Shalom Auerbach
owner
CConversion
Common Stock, par value $0.001 per shareindirect: See Footnote
+53,468--1,789,774Jan 14, 2025
Aug 2, 2024Shalom Auerbach
owner
CConversion
Common Stock, par value $0.001 per shareindirect: See Footnote
+131,472--1,921,246Jan 14, 2025
Aug 2, 2024Shalom Auerbach
owner
CConversion
Common Stock, par value $0.001 per shareindirect: See Footnote
+78,710--1,999,956Jan 14, 2025
Aug 2, 2024Shalom Auerbach
owner
CConversion
Common Stock, par value $0.001 per shareindirect: See Footnote
+88,940--2,088,896Jan 14, 2025
Aug 2, 2024Shalom Auerbach
owner
CConversion
Common Stock, par value $0.001 per shareindirect: See Footnote
+179,027--2,267,923Jan 14, 2025
Aug 2, 2024Shalom Auerbach
owner
CConversion
Common Stock, par value $0.001 per shareindirect: See Footnote
+51,035--2,318,958Jan 14, 2025
Aug 2, 2024Shalom Auerbach
owner
CConversion
Common Stock, par value $0.001 per shareindirect: See Footnote
+178,135--2,497,093Jan 14, 2025
Aug 2, 2024Shalom Auerbach
owner
CConversion
Common Stock, par value $0.001 per shareindirect: See Footnote
+50,838--2,547,931Jan 14, 2025
Aug 2, 2024Shalom Auerbach
owner
CConversion
Convertible Promissory Notederivative
-$0.00-0Jan 14, 2025
Aug 2, 2024Shalom Auerbach
owner
CConversion
Convertible Promissory Notederivativeindirect: See Footnote
-$0.00-0Jan 14, 2025
Aug 2, 2024Shalom Auerbach
owner
CConversion
Convertible Promissory Notederivativeindirect: See Footnote
-$0.00-0Jan 14, 2025
Aug 2, 2024Shalom Auerbach
owner
CConversion
Convertible Promissory Notederivativeindirect: See Footnote
-$0.00-0Jan 14, 2025
Aug 2, 2024Shalom Auerbach
owner
CConversion
Convertible Promissory Notederivativeindirect: See Footnote
-$0.00-0Jan 14, 2025
Aug 2, 2024Shalom Auerbach
owner
CConversion
Convertible Promissory Notederivativeindirect: See Footnote
-$0.00-0Jan 14, 2025
Aug 2, 2024Shalom Auerbach
owner
CConversion
Convertible Promissory Notederivativeindirect: See Footnote
-$0.00-0Jan 14, 2025
Aug 2, 2024Shalom Auerbach
owner
CConversion
Convertible Promissory Notederivativeindirect: See Footnote
-$0.00-0Jan 14, 2025
Aug 2, 2024Shalom Auerbach
owner
CConversion
Convertible Promissory Notederivativeindirect: See Footnote
-$0.00-0Jan 14, 2025
Aug 2, 2024Shalom Auerbach
owner
CConversion
Convertible Promissory Notederivativeindirect: See Footnote
-$0.00-0Jan 14, 2025
Aug 2, 2024Shalom Auerbach
owner
CConversion
Convertible Promissory Notederivativeindirect: See Footnote
-$0.00-0Jan 14, 2025
Aug 2, 2024Shalom Auerbach
owner
CConversion
Convertible Promissory Notederivativeindirect: See Footnote
-$0.00-0Jan 14, 2025

Insiders

Everyone who has filed a Form 4 here.

Questions about OSTX

Answered from the filings on this page, as of the latest one.

Are insiders buying OSTX?

No. In the last 90 days no insider at OS Therapies Inc bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.

Who was the last insider to trade OSTX on the open market?

Shalom Auerbach (10% owner) sold $164k of OSTX on May 7, 2025 and filed the Form 4 on May 9, 2025. InsiderTell scored 23 (weak).

How many insiders file Form 4 at OS Therapies Inc?

9 people have filed a Form 4 at OS Therapies Inc, among them Christopher P. Acevedo (Chief Financial Officer), Shalom Auerbach (10% owner), John Ciccio (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

OSTX insider trading: OS Therapies Inc | InsiderTell